Market Place
Sourcing Support
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
12 Sep 2024 //
GLOBENEWSWIRE
Cingulate Achieves Milestone in CTx-1301 ADHD Drug Development for FDA Clearance
25 Jun 2024 //
GLOBENEWSWIRE
FDA Clears Cingulate To File For CTx-1301 ADHD Approval
21 May 2024 //
GLOBENEWSWIRE
Cingulate Announces Presentation of Full Trial Results from Phase 3 of CTx-1301
05 Sep 2023 //
GLOBENEWSWIRE
Journal Frontiers in Psychiatry Publishes Analysis of With ADHD
26 Jun 2023 //
PR NEWSWIRE
Cingulate Completes PIII Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
08 Jun 2023 //
GLOBENEWSWIRE
Corium`s Medication AZSTARYS Had No Significant Impact on Children`s Weight
22 May 2023 //
PR NEWSWIRE
Cingulate Announces Successful Transfer of CTx-1301 dexmethylphenidate
03 May 2023 //
GLOBENEWSWIRE
Corium`s Novel ADHD Medication AZSTARYS Shown Safe and Effective in Study
22 Feb 2023 //
PR NEWSWIRE
Corium to Present Positive Data on AZSTARYS and ADLARITY at Psych Congress 2022
13 Sep 2022 //
PRNEWSWIRE
Serdexmethylphenidate Has Low Relative Potential for Abuse
01 Jun 2022 //
BIOSPACE
Corium To Present at Academy of Managed Care Pharmacy
28 Mar 2022 //
PRNEWSWIRE
Ark Bio Enters Into Excl License Agreement for Azstarys
29 Dec 2021 //
ASIAONE
Once-Daily AZSTARYS® , First &Only Product Containing Dexmethylphenidate Prodrug
14 Oct 2021 //
PRNEWSWIRE
Corium Secures $235 Million in Debt Financing
27 Sep 2021 //
PRNEWSWIRE
ADHD drug developer Cingulate sets terms for $50 million IPO
27 Sep 2021 //
RENAISSANCECAPITAL
KemPharm Announces FDA Approval of AZSTARYS™
03 Mar 2021 //
GLOBENEWSWIRE
U.S. Food and Drug Administration Approves Novel Once-Daily Capsule AZSTARYS™
03 Mar 2021 //
PRNEWSWIRE
Granules`s Generic Dexmethylphenidate Hydrochloride Receives Approval In US
09 Sep 2020 //
FDA
FDA Consults on Abuse-Deterrent CNS Stimulants
20 Sep 2019 //
RAPS
Alkem Labs` Generic Dexmethylphenidate Hydrochloride Receives Approval in US
24 Jul 2019 //
FDA
Lannett enters into distribution agreement with Adare
22 Oct 2018 //
PRESS RELEASE
Cediprof`s Generic Dexmethylphenidate Hydrochloride Receives Approval in US
22 Sep 2018 //
FDA
BDD Pharma and Cingulate Therapeutics Announce License Agreement
10 Sep 2018 //
PR NEWSWIRE
Cingulate raises $7.5m for controlled-release ADHD therapy
11 Jul 2018 //
DRUG DEL NEWS
Lannett’s Generic Dexmethylphenidate Hydrochloride Receives Approval In US
27 Sep 2017 //
FDA
Impax Lab’s Generic Dexmethylphenidate Hydrochloride Receives Approval In US
06 Jul 2017 //
FDA
Impax Announces FDA Approval of Generic Focalin XR Dexmethylphenidate HCL
05 Jul 2017 //
PR NEWSWIRE
ShangPharma Innovation Appoints Mohamad Moghadam-Tabrizi as Senior Vice Presiden
24 May 2017 //
PR NEWSWIRE
Intellipharmaceutic Reports on Launch of Additional Strengths of Generic Focalin
06 Jan 2017 //
GLOBENEWSWIRE
Par`s Generic Dexmethylphenidate HCL Receives Approval In US
30 Nov 2016 //
FDA
Novel`s Generic Dexmethylphenidate Hcl Tentatively Approved in US For ADHD
12 May 2015 //
FDA
Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc
10 Mar 2015 //
ALKERMES
